In the present study, our findings showed that overexpression of p-Mnk1 and p-eIF4E was significantly associated with poor overall survival of NSCLC patients and high expression of p-Mnk1 could serve as a poor prognostic biomarker for these patients, so targeting Mnk/eIF4E pathway for blocking Mnk function and eIF4E phosphorylation might be a potential therapeutic strategy for treatment of NSCLC patients, particularly for these patients with overexpression of p-eIF4E and p-Mnk1. This evidence concerns the gene MKNK1 and non-small cell lung carcinoma.